Making the case for allo durability at #ASCO23 with Allogene’s CEO
Allogene CEO David Chang describes the data his company presented at ASCO on Saturday and makes the case for the durability of the response.
top of page
Follow BiotechTV
Also look for unique social pages for BiotechTV U.
Popular
#1. Pfizer’s CEO on Q2 earnings.
#2. Moderna CEO Stéphane Bancel on Moderna’s business at its R&D Day in New York
#3. UPenn’s Bruce Levine discusses the progress of CAR-T
#4. Learning about gene writing at Tessera Therapeutics
#5. Visiting Bayer’s Research and Innovation Center in Kendall Square
bottom of page